# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
UBS analyst Andrew Mok maintains DaVita (NYSE:DVA) with a Buy and raises the price target from $169 to $175.
DaVita Inc. (NYSE:DVA) ("DaVita") announced today that it has commenced a private offering (the "offering") of ...
B of A Securities analyst Kevin Fischbeck maintains DaVita (NYSE:DVA) with a Underperform and raises the price target from $...
Outlook:The following forward-looking measures and the underlying assumptions involve significant known and unknown risks and u...
DaVita (NYSE:DVA) reported quarterly earnings of $2.59 per share which beat the analyst consensus estimate of $2.54 by 1.97 per...
TD Cowen analyst Gary Taylor maintains DaVita (NYSE:DVA) with a Hold and raises the price target from $139 to $150.
DaVita Inc., a kidney dialysis provider, will pay $34.5 million for allegedly paying kickbacks to competitors and doctors for p...